Trial Profile
Long-Term Treatment Study of Ocrelizumab for Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2022
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 27 May 2016 New trial record